Amneal Pharmaceuticals, Inc. 8-K

What Happened
Amneal Pharmaceuticals announced in an 8-K (filed Jan 28, 2026) that it will make effective a Nationwide Opioids Settlement Agreement on January 29, 2026. The agreement settles a substantial majority of opioid-related claims brought by states and subdivisions that sued the company, with participation from all eligible state and territorial attorneys general and previously suing subdivisions.

Key Details

• Cash payment: $88.5 million to participating states and subdivisions.
• Product commitment: Up to $177.4 million in naloxone nasal spray (valued at $125 per twin pack).
• Cash alternative: Settling parties may opt to receive 25% of the naloxone value (up to $44.4M) in cash during the last 4 years of a 10-year payment term — which could raise Amneal’s total cash payout to as much as $132.9M.
• Effective date and filing: Settlement becomes effective Jan 29, 2026; 8-K signed Jan 28, 2026 by Jason B. Daly, EVP & Chief Legal Officer.

Why It Matters
This settlement resolves a large portion of Amneal’s opioid-related litigation exposure, replacing extended litigation risk with a defined payment and product commitment. For investors, the agreement clarifies potential near- and medium-term cash and product obligations (up to ~$132.9M cash exposure if parties elect cash for part of the naloxone). The settlement may reduce legal uncertainty and future litigation expenses tied to these specific opioid claims.